**Supplementary Table 1.** Clinical characteristics of evaluated patients and healthy controls.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **HC** | **NMOsd** | **MS** | **NPSLE** |
| **Gender** |  |  |  |  |
|  Female/male (n) | 27 / 12 | 18 / 1 | 38 / 4 | 34 / 1 |
| **Age (years)** |  |  |  |  |
|  Median | 25 | 44 | 32 | 33 |
|  Min-max range | 20 - 57 | 24 - 76 | 22 - 49 | 18 - 55 |
| **Duration (years)** |  |  |  |  |
|  Median | - | 8 | 5 | 3 |
|  Min-max range | - | 2 - 30 | 0.3 - 26 | 0.2 - 22 |
| **EDSS score** |  |  |  |  |
|  Median | - | 4 | 1 | - |
|  Min-max range | - | 1 - 9 | 0 - 6 | - |
| **SLEDAI score** |  |  |  |  |
|  Median | - | - | - | 17 |
|  Min-max range | - | - | - | 6 - 55 |

HC: healthy controls; NMOsd: neuromyelitis optica spectrum disorders; MS: multiple sclerosis; NPSLE: neuropsychiatric systemic lupus erythematosus; EDSS: Kurtzke Expanded Disability Status Scale; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index.